Analysts UBS lowered Zealand Pharma (ZEAL) price target to 540 Danish kroner amid concerns over survodutide’s tolerability
Zealand Pharma's stock has faced significant declines following disappointing data on its weight loss drug survodutide, leading analysts to reduce sales forecasts and shift focus to its other drug, petrelintide, which may offer better prospects in the obesity market.